1.Clinical and prognostic analysis of 52 patients with gastric neuroendocrine carcinoma
Huabin CHENG ; Hao HU ; Hong CHEN
Chinese Journal of General Surgery 2016;31(6):445-448
Objective To investigate the clinical features,diagnosis,treatment and prognosis of gastric neuroendocrine carcinoma (G-NEC).Methods Clinical data of 52 G-NEC cases were analyzed.Follow-up was conducted by telephone.The survival curves were drawn using Kaplan-Meier method.Univariate analysis was performed by the Log-rank test and multivariate analysis was performed by COX proportional hazards model.Results The median overall survival rate was 19 months (range 6 to61 months),and the overall 1,3,5-year survival rates were 74%,16% and 5% respectively.Tumor stage surgery,vascular nerve involvement and Ⅲ and Ⅳ phase chemotherapy were related to prognosis (x2 =24.254,10.005,7.261,8.790,all P < 0.05).Multivariate analysis showed tumor stage and vascular nerve involvement were independent prognostic factors (x2 =17.170,5.810,all P < 0.05).Conclusion G-NEC is a highly malignant tumor with poor prognosis.Preoperative diagnosis rate is low.Surgery is the treatment of first choice.Definite diagnosis depends on postoperative pathology and immunohistochemical examination.
2.Decreased expression of Foxp3 in patients with allergic rhinitis
Zhonglin MOU ; Zhibin ZHAO ; Huabin LI ; Yenong TAN ; Lei CHENG
Chinese Archives of Otolaryngology-Head and Neck Surgery 2006;0(06):-
OBJECTIVE To evaluate the role of forkhead transcription factor p3(Foxp3) in the pathogenesis of allergic rhinitis(AR).METHODS Nasal tissues and peripheral blood mononuclear cells(PBMCs) were obtained from 17 patients with AR and 11 controls.Foxp3 was detected in nasal tissues by immunohistochemisry and real-time reverse transcription polymerase chain reaction(RT-PCR).Foxp3 and CD4+CD25+T cells were evaluated in PBMCs by using ? ow cytometry.RESULTS The numbers of Foxp3+ cells was(44.2?20.5)cells/mm2 and(129.5? 35.6)cells/mm2 in nasal mucosa of two groups(P
3.Study of regimen based on L-asparaginase for 36 cases with nasal type extranodal NK/T cell lymphoma
Huabin HU ; Meizuo ZHONG ; Enyi LIU ; Tingting CHENG ; Jin HUANG ; Bin LI ; Youhong TANG
Journal of Leukemia & Lymphoma 2012;21(3):153-156
Object To evaluate the efficacy and toxicity of L-asparaginase based regimen for extranodal nasal type NK/T cell lymphoma (ENKTL).Methods 36 patients were treated with L-asparaginase based regimen from February 2008 to November 2011. 20 stage Ⅰ /Ⅱ patients were administered with VLD regimen based chemo-radiotherapy. 4 of 16 stage Ⅲ/Ⅳ patients received modified SMILE regimen chemotherapy, followed by involved field radiation therapy (IFRT), while others received modified SMILE regimen chemotherapy alone.Results Among 36 patients,35 were eligible for treatment response evaluation.The overall response rate (RR) was 68.6% (24/35) with complete response (CR) rate of 54.3% (19/35).After the median follow-up of 13.5 (range 3-31) months,for all patients,the 1-year overall survival (OS) rate was 82 %,and the rate of progression-free survival (PFS) at 1 year was 65 %.The patients who attained response with treatment showed better 1-year OS (93 %) and PFS (80 %) as compared with patients without response (35 %; 33 %),and the differences were statistically significant (x2=13.909,P =0.000; x2=8.216,P =0.004).The major adverse event was myelosuppression. No chemotherapy-related mortality occurred. Conclusion L-asparaginase based regimen is obviously effective and well tolerant for ENKTL. The large prospective clinical trials of L-asparaginase based regimen in the first-line treatment for ENKTL are worth for further investigation.
5.Effects of serum cytokines on antipsychotic medication treatment in schizophrenia patients
Guangman ZHANG ; Ying LI ; Wen ZHANG ; Qinghao TONG ; Wanqing YU ; Zhiwen GAO ; Fengxian CHENG ; Xiaohong DAN ; Kun WANG ; Jingjing CHENG ; Huan LIU ; Qin HUANG ; Huabin XU
International Journal of Laboratory Medicine 2017;38(6):735-736
Objective To study the levels of serum cytokines in schizophrenic patients and their changes in antipsychotic medica-tion treatment .Methods The levels of serum cytokines including IL-10 ,IL-6 ,IL-13 ,IL-4 ,IFN ,TNF-α,IL-1a and IL-1RA were de-tected in 34 healthy adults and 53 schizophrenia patients by adopting the flow fluorescence method .Results The serum levels of IL-6 ,IL10 and TNF-αbefore treatment in schizophrenic patients were significantly higher than those in the control group (P<0 .05) . After treatment ,the levels of serum IL-1a ,IL-6 and TNF-α in schizophrenic patients were significantly lower than those before treatment(P<0 .05) .Conclusion Serum IL-6 and TNF-α levels are correlated with the disease condition of schizophrenia .IL-10 plays a role in early anti-inflammation of schizophrenia .
6.Neoadjuvant strategy for locally advanced colorectal cancer based organ preservation
Zehua WU ; Yi CHENG ; Huabin HU ; Jianwei ZHANG ; Yanhong DENG
Chinese Journal of Gastrointestinal Surgery 2024;27(4):416-423
Neoadjuvant therapy for locally advanced colorectal cancer has made great progress in the past 20 years, but there are still limitations such as side effects, organ dysfunction and unsatisfactory control of metastasis. In recent years, with the improvement of surgical techniques and further development of molecular research, how to further improve local control, reduce distant metastasis, and even avoid surgery according to clinical remission to achieve organ preservation, is the current demand and research goal. With the advancement of molecular research, colorectal cancer has different treatment strategies based on microsatellite status. For patients with microsatellite instability locally advanced colorectal cancer, immune checkpoint inhibitor therapy significantly increased the pathologic complete response rate, reduced the incidence of adverse events and improved organ function compared with conventional chemoradiotherapy. For patients with microsatellite stable locally advanced colon cancer, neoadjuvant therapy is still in the exploratory stage. The standard of care is surgery combined with perioperative chemotherapy. For microsatellite stable locally advanced rectal cancer, the complete response rate is improved by enhancing neoadjuvant therapy, which helps to preserve organs. On the other hand, selective radiotherapy preserves organ function and improves quality of life. This article reviews the neoadjuvant treatment strategies for locally advanced colorectal cancer based on organ-sparing strategies.
7.Neoadjuvant strategy for locally advanced colorectal cancer based organ preservation
Zehua WU ; Yi CHENG ; Huabin HU ; Jianwei ZHANG ; Yanhong DENG
Chinese Journal of Gastrointestinal Surgery 2024;27(4):416-423
Neoadjuvant therapy for locally advanced colorectal cancer has made great progress in the past 20 years, but there are still limitations such as side effects, organ dysfunction and unsatisfactory control of metastasis. In recent years, with the improvement of surgical techniques and further development of molecular research, how to further improve local control, reduce distant metastasis, and even avoid surgery according to clinical remission to achieve organ preservation, is the current demand and research goal. With the advancement of molecular research, colorectal cancer has different treatment strategies based on microsatellite status. For patients with microsatellite instability locally advanced colorectal cancer, immune checkpoint inhibitor therapy significantly increased the pathologic complete response rate, reduced the incidence of adverse events and improved organ function compared with conventional chemoradiotherapy. For patients with microsatellite stable locally advanced colon cancer, neoadjuvant therapy is still in the exploratory stage. The standard of care is surgery combined with perioperative chemotherapy. For microsatellite stable locally advanced rectal cancer, the complete response rate is improved by enhancing neoadjuvant therapy, which helps to preserve organs. On the other hand, selective radiotherapy preserves organ function and improves quality of life. This article reviews the neoadjuvant treatment strategies for locally advanced colorectal cancer based on organ-sparing strategies.
8.Current status and prospect of biomarker research for schizophrenia
Mengyuan ZHU ; Qing CHEN ; Dan LI ; Mengxia WANG ; Renyu WANG ; Yuxin ZHU ; Weifeng JIN ; Shuzi CHEN ; Ping LI ; Zhenhua LI ; Peijun MA ; Shuai LIU ; Qiong GAO ; Xiaoyan LOU ; Jie XU ; Lili ZHU ; Ling ZHAO ; Kangyi LIANG ; Jinghong CHEN ; Xunjia CHENG ; Ke DONG ; Xiaokui GUO ; Qingtian LI ; Yun SHI ; Junyu SUN ; Huabin XU ; Ping LIN
Chinese Journal of Laboratory Medicine 2022;45(11):1191-1196
Schizophrenia is a serious mental disease. The diagnosis of schizophrenia so far relies heavily on subjective evidence, including self-reported experiences by patients, manifestations described by relatives, and abnormal behaviors assessed by psychiatrists. The diagnosis, monitoring of the disease progression and therapy efficacy assessment are challenging due to the lack of established laboratory biomarkers. Based on the current literature, clinical consensus, guidelines, and expert recommendations, this review highlighted evidence-based potential laboratory biomarkers for the diagnosis of schizophrenia, including genetic biomarkers, neurotransmitters, neurodevelopmental-related proteins, and intestinal flora, and discussed the potential future directions for the application of these biomarkers in this field, aiming to provide an objective basis for the use of these biomarkers in the early and accurate diagnosis, treatment, and prognosis and rehabilitation assessment of schizophrenia.
9.Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis.
Lei CHENG ; Jianjun CHEN ; Qingling FU ; Shaoheng HE ; Huabin LI ; Zheng LIU ; Guolin TAN ; Zezhang TAO ; Dehui WANG ; Weiping WEN ; Rui XU ; Yu XU ; Qintai YANG ; Chonghua ZHANG ; Gehua ZHANG ; Ruxin ZHANG ; Yuan ZHANG ; Bing ZHOU ; Dongdong ZHU ; Luquan CHEN ; Xinyan CUI ; Yuqin DENG ; Zhiqiang GUO ; Zhenxiao HUANG ; Zizhen HUANG ; Houyong LI ; Jingyun LI ; Wenting LI ; Yanqing LI ; Lin XI ; Hongfei LOU ; Meiping LU ; Yuhui OUYANG ; Wendan SHI ; Xiaoyao TAO ; Huiqin TIAN ; Chengshuo WANG ; Min WANG ; Nan WANG ; Xiangdong WANG ; Hui XIE ; Shaoqing YU ; Renwu ZHAO ; Ming ZHENG ; Han ZHOU ; Luping ZHU ; Luo ZHANG
Allergy, Asthma & Immunology Research 2018;10(4):300-353
Allergic rhinitis (AR) is a global health problem that causes major illnesses and disabilities worldwide. Epidemiologic studies have demonstrated that the prevalence of AR has increased progressively over the last few decades in more developed countries and currently affects up to 40% of the population worldwide. Likewise, a rising trend of AR has also been observed over the last 2–3 decades in developing countries including China, with the prevalence of AR varying widely in these countries. A survey of self-reported AR over a 6-year period in the general Chinese adult population reported that the standardized prevalence of adult AR increased from 11.1% in 2005 to 17.6% in 2011. An increasing number of original articles and imporclinical trials on the epidemiology, pathophysiologic mechanisms, diagnosis, management and comorbidities of AR in Chinese subjects have been published in international peer-reviewed journals over the past 2 decades, and substantially added to our understanding of this disease as a global problem. Although guidelines for the diagnosis and treatment of AR in Chinese subjects have also been published, they have not been translated into English and therefore not generally accessible for reference to non-Chinese speaking international medical communities. Moreover, methods for the diagnosis and treatment of AR in China have not been standardized entirely and some patients are still treated according to regional preferences. Thus, the present guidelines have been developed by the Chinese Society of Allergy to be accessible to both national and international medical communities involved in the management of AR patients. These guidelines have been prepared in line with existing international guidelines to provide evidence-based recommendations for the diagnosis and management of AR in China.
Adult
;
Asian Continental Ancestry Group*
;
China
;
Comorbidity
;
Developed Countries
;
Developing Countries
;
Diagnosis*
;
Epidemiologic Studies
;
Epidemiology
;
Global Health
;
Humans
;
Hypersensitivity*
;
Prevalence
;
Rhinitis, Allergic*
10.Chinese Society of Allergy and Chinese Society of Otorhinolaryngology-Head and Neck Surgery Guideline for Chronic Rhinosinusitis
Zheng LIU ; Jianjun CHEN ; Lei CHENG ; Huabin LI ; Shixi LIU ; Hongfei LOU ; Jianbo SHI ; Ying SUN ; Dehui WANG ; Chengshuo WANG ; Xiangdong WANG ; Yongxiang WEI ; Weiping WEN ; Pingchang YANG ; Qintai YANG ; Gehua ZHANG ; Yuan ZHANG ; Changqing ZHAO ; Dongdong ZHU ; Li ZHU ; Fenghong CHEN ; Yi DONG ; Qingling FU ; Jingyun LI ; Yanqing LI ; Chengyao LIU ; Feng LIU ; Meiping LU ; Yifan MENG ; Jichao SHA ; Wenyu SHE ; Lili SHI ; Kuiji WANG ; Jinmei XUE ; Luoying YANG ; Min YIN ; Lichuan ZHANG ; Ming ZHENG ; Bing ZHOU ; Luo ZHANG
Allergy, Asthma & Immunology Research 2020;12(2):176-237
The current document is based on a consensus reached by a panel of experts from the Chinese Society of Allergy and the Chinese Society of Otorhinolaryngology-Head and Neck Surgery, Rhinology Group. Chronic rhinosinusitis (CRS) affects approximately 8% of Chinese adults. The inflammatory and remodeling mechanisms of CRS in the Chinese population differ from those observed in the populations of European descent. Recently, precision medicine has been used to treat inflammation by targeting key biomarkers that are involved in the process. However, there are no CRS guidelines or a consensus available from China that can be shared with the international academia. The guidelines presented in this paper cover the epidemiology, economic burden, genetics and epigenetics, mechanisms, phenotypes and endotypes, diagnosis and differential diagnosis, management, and the current status of CRS in China. These guidelines—with a focus on China—will improve the abilities of clinical and medical staff during the treatment of CRS. Additionally, they will help international agencies in improving the verification of CRS endotypes, mapping of eosinophilic shifts, the identification of suitable biomarkers for endotyping, and predicting responses to therapies. In conclusion, these guidelines will help select therapies, such as pharmacotherapy, surgical approaches and innovative biotherapeutics, which are tailored to each of the individual CRS endotypes.
Adult
;
Asian Continental Ancestry Group
;
Biomarkers
;
China
;
Consensus
;
Diagnosis
;
Diagnosis, Differential
;
Drug Therapy
;
Eosinophils
;
Epidemiology
;
Epigenomics
;
Genetics
;
Humans
;
Hypersensitivity
;
Inflammation
;
International Agencies
;
Medical Staff
;
Neck
;
Phenotype
;
Precision Medicine